Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Update

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 5,940,000 shares, a decrease of 6.2% from the October 31st total of 6,330,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 5.0 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BDTX shares. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday, November 6th. Piper Sandler upped their target price on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 price target on shares of Black Diamond Therapeutics in a research report on Tuesday, October 8th.

Institutional Trading of Black Diamond Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of Black Diamond Therapeutics by 6.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,224 shares of the company’s stock valued at $475,000 after purchasing an additional 7,021 shares in the last quarter. Walleye Capital LLC purchased a new stake in Black Diamond Therapeutics in the third quarter worth $49,000. MetLife Investment Management LLC increased its stake in shares of Black Diamond Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,286 shares of the company’s stock worth $97,000 after acquiring an additional 12,557 shares in the last quarter. Intech Investment Management LLC bought a new stake in Black Diamond Therapeutics during the third quarter worth about $56,000. Finally, Vontobel Holding Ltd. purchased a new stake in Black Diamond Therapeutics in the third quarter worth about $68,000. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Stock Down 1.5 %

BDTX traded down $0.04 during midday trading on Tuesday, hitting $2.55. The stock had a trading volume of 101,360 shares, compared to its average volume of 792,792. The business has a fifty day moving average of $3.21 and a 200 day moving average of $4.61. Black Diamond Therapeutics has a 1 year low of $2.23 and a 1 year high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09. On average, analysts forecast that Black Diamond Therapeutics will post -1.3 earnings per share for the current fiscal year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.